2026年2月10日，ST华鹏（维权）（sh603021）触及跌停，跌停价5.99元，涨幅-4.92%，总市值19.16亿 元，流通市值19.16亿元，截止发稿，总成交额7775.19万元。 根据喜娜AI异动分析，ST华鹏跌停原因可能如下，业绩亏损+游资波动+年报预期： 1、公司经营业绩 不佳：2025年报业绩预告显示归母净利润 -2.63亿~ -1.94亿，亏损大幅增加，这反映出公司经营状况 差，盈利能力大幅下降，对股价形成强大的压力。 2、游资参与带来不确定性：2月5日该股入选龙虎 榜，成交额达1.2亿，由游资推动上榜。游资快进快出的特点使得股价波动较大，虽然当时资金流入推 动股价短期上升，但也增加了后续股价大幅变动的不确定性，可能是跌停的诱因之一。 3、概念题材与 市场热点分析：ST华鹏属于ST板块，ST板块通常是问题股集中的板块，市场对这类股票较为谨慎。在 当前市场环境下，投资者更倾向于业绩良好、发展稳定的企业，ST华鹏业绩亏损的情况使其在市场中 缺乏吸引力，同板块其他业绩不佳的股票也常出现股价大幅波动甚至跌停的情况。 4、技术面及资金流 向分析：结合近期情况，公司业绩亏损的利空因素可能导致部分资金流 ...

2026年2月10日，*ST精伦（sh600355）触及跌停，跌停价1.38元，涨幅-5.07%，总市值6.45亿元，流通 市值6.45亿元，截止发稿，总成交额21.92万元。 声明：市场有风险，投资需谨慎。本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 责任编辑：小浪快报 根据喜娜AI异动分析，*ST精伦跌停原因可能如下，业绩亏损+市场交易+股价波动： 1、业绩亏损压 力：2026年1月28日业绩预告显示2025年报亏损小幅增加，归母净利润 -4550万~ -3950万。业绩亏损增 加对公司股价形成一定压力，投资者对公司的盈利预期降低，进而影响股价表现，这是导致跌停的重要 因素。 2、市场交易因素：2026年2月6日发生4笔大宗交易，虽然折溢率为0表明交易价格与市场价格一 致 ...

2月5日，深康佳A盘中大跌超8%，收跌6.79%，公司股价已经连续7个交易日下跌，期间两日跌停，累计跌幅近30%。前一日盘后，因连续3个交易日收盘价 格跌幅偏离值累计超过20%，触发股票异常交易波动公告。 | 项目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司 | 亏损:1,557,300万元 至 1,258,100 | 亏损:329,558.87 万元 | | 股东的净利润 | 力元 | | | 扣除非经常性损 | 亏损:1,026,300万元 至 995,300万 | 亏损:320.550.41万元 | | 益后的净利润 | 元 | | | 基本每股收益 | 亏损:6.4674元/股 至 5.2246元/股 | 亏损:1.3686元/股 | | 营业收入 | 900,000 万元 至 1,050,000 万元 | 1.111.476.40 万元 | | 扣除后营业收入 | 850,000 万元 至 1,000,000 万元 | 1,051,236.57 万元 | | 项目 | 本会计年度末 | 上年末 | | 归属于上市公司 股东的净资产 | -533.400 ...

Core Viewpoint - JuShi Chemical (688669.SH) has been penalized by the China Securities Regulatory Commission (CSRC) for inflating its 2023 semi-annual revenue through false trading practices, resulting in a total fine of 6.7 million yuan [1][2]. Regulatory Penalties - The penalties stem from an investigation initiated in November 2025, with a prior notice of administrative punishment issued in January 2026 [2]. - JuShi Chemical and its subsidiaries engaged in three types of fictitious trading operations, inflating revenue by a total of 157 million yuan, which accounted for 8.32% of total revenue, 8.51% of total costs, and reduced profit by 166,290 yuan [2][3]. Management Accountability - The former chairman and general manager, Chen Gang, was fined 1.8 million yuan for failing to control the fraudulent activities, while other executives received fines totaling 2.5 million yuan for their roles in the misconduct [3]. - The company has also received a regulatory notice for issues related to inaccurate revenue accounting, undisclosed related-party transactions, and inadequate internal controls [3]. Financial Performance - JuShi Chemical has faced declining financial performance, with a projected net loss of 90 million to 120 million yuan for 2025, despite a reduction in losses compared to 2024 [4]. - The company's net profit has decreased significantly over the past three years, with a loss of 236 million yuan in 2024, despite a revenue increase of 10.72% to 4.08 billion yuan [5].

（文/孙梅欣 编辑/张广凯） 业绩亏损、信托追债，良品铺子的麻烦似乎在进入2026年之后集中出现。 良品铺子在2月3日晚间发布公告，因控股股东及实控人2024年1月向信托的一笔2.8亿元规模的债务逾 期，被武汉市西湖区人民法院下发了执行通知。 公告还提到，控股股东所质押的良品铺子股权可能存在被强制执行的可能，这也可能造成良品铺子控股 股东持股权益的变化。 这一执行通知，也直接引来上交所对良品铺子及董事、高管、控股股东和实控人下发的监管工作函，显 示监管机构对此事的重视。 与此同时，良品铺子控股股东和早前意向投资人广州轻工的诉讼还在继续。公告显示，原本在在去年上 半年计划引入作为投资人的广州轻工，要求良品铺子解除原股权转让协议，并要求支付违约金、财产保 全损失等多项损失在内的2073万余元。据悉，这一诉讼已经被法院受理但还暂未开庭。 一方面控股股东的债务和诉讼尚未解决，另一方面良品铺子公布的去年业绩预告中，再度出现亏损。 根据公司业绩预告显示，良品铺子2025年预计归母净亏损1.2亿元—1.6亿元之间，归母扣非净亏损在1.5 亿元—1.9亿元之间，在去年基础上，亏损金额进一步扩大。 对于良品铺子而言，当多重问题 ...

ST华鹏公告称，公司股票于2026年2月3 - 4日连续两个交易日涨停，价格波动大，涨幅高于同期上证指 数。2026年1月24日业绩预告显示，预计2025年净利润为-2.63亿元至 - 1.94亿元，期末净资产为-2.08亿 元到 - 1.39亿元，业绩亏损且净资产为负。经测算，公司股票在2025年年度报告披露后可能被上交所实 施退市风险警示。截至公告日，公司主营、经营情况无重大变化，也无应披露未披露重大事项。 ...

Core Viewpoint - The significant decline in the stock price of Qunxing Toys is attributed to poor financial performance, obstacles in capital increase plans, and shareholder disagreements, leading to decreased investor confidence [1] Financial Performance - Qunxing Toys is expected to report a substantial loss for 2025, with a projected net profit loss ranging from -37 million to -25 million, indicating an increase in losses by 35.9% to 101.2% compared to previous forecasts [1] - The non-recurring loss is anticipated to widen by 12.5% to 66.6%, reflecting a decline in the company's profitability [1] Capital Increase and Governance Issues - The company's capital increase plan has faced delays, with multiple extensions of the authorization period, indicating challenges in implementation [1] - There is notable dissent among shareholders, with 5% to 7% of votes against several proposals, highlighting significant disagreements regarding dividend management policies [1] Market Sentiment and Trading Activity - On February 3, 2026, Qunxing Toys was included in the "Dragon and Tiger List," with selling amounts exceeding buying amounts, suggesting a high level of market disagreement [1] - The upcoming annual report, expected to be released on April 28, 2026, is likely to be unfavorable given the prior significant loss forecasts, further impacting investor sentiment [1]

长江商报消息 面对沉重的历史包袱与持续的经营压力，红相股份（维权）（300427.SZ）正试图通过资 产处置奋力自救。 2月2日晚间，红相股份披露资产出售计划。公司拟以1.2亿元的价格，转让一笔账面价值约2.05亿元、已 累计计提减值准备超1亿元的涉光伏项目收款权。 长江商报记者注意到，本次交易源自两年前红相股份一笔资产剥离。通过处置此笔已大幅减值的收款 权，红相股份不仅旨在解决特定债权的回收难题，更是其回笼资金、优化资产结构以改善资产质量的关 键一步。 日前，红相股份发布业绩预告。2025年，公司预计将实现营业收入7亿元至7.5亿元，同比增长10.25%至 18.13%；归属于上市公司股东的净利润（以下简称"归母净利润"）亏损1300万元至2600万元，扣除非经 常性损益后的净利润（以下简称"扣非净利润"）亏损4900万元至6200万元。至此，红相股份已连续三年 亏损，归母净利润亏损额累计超过8亿元。 拟出售的收款权累计减值准备1.04亿 红相股份本次资产出售与两年前的一笔交易相关。 长江商报记者注意到，2023年10月，红相股份曾公开挂牌转让全资子公司卧龙电气银川变压器有限公司 （以下简称 "银川变压器" ...

Core Viewpoint - The report indicates that 港通医疗 (Sichuan Porton Medical Equipment Group Co., Ltd.) is facing a projected loss for the year 2025, marking a significant shift from profit to loss, alongside delays in some fundraising projects due to external factors [1] Group 1: Stock Performance - As of February 3, 2026, 港通医疗's stock closed at 25.21 yuan, reflecting a 4.0% increase from the previous trading day [1] - The stock opened at 24.76 yuan, reached a high of 25.47 yuan, and a low of 24.22 yuan, with a trading volume of 73.46 million yuan and a turnover rate of 4.51% [1] Group 2: Regulatory Compliance - The report from 中信建投证券 (CITIC Securities) regarding the 2025 annual continuous supervision inspection indicates that the company is generally compliant in areas such as corporate governance, internal control, information disclosure, and use of raised funds [1] - However, the company is expected to incur a loss between 2 million to 4 million yuan for the year 2025, which is a reversal from previous profits [1] - Some fundraising projects are experiencing slower construction progress than anticipated, leading to the execution of delay procedures and subsequent announcements [1]

Core Viewpoint - Recently, Di Rui Medical (300396), part of the China Resources Group's IVD platform, announced a forecast for a net profit loss of between 180 million to 350 million yuan for the fiscal year 2025, marking the first annual loss since its listing 11 years ago [1] Group 1: Financial Performance - The company reported a profit of 15.68 million yuan in Q1 of the previous year, but shifted to a loss of 43.99 million yuan in Q2 and further expanded the loss to 58.94 million yuan in Q3, indicating a continuous deterioration in performance [1] - The expected losses are attributed to intensified market competition, asset impairment, and several operational challenges, particularly in the domestic market [1] - The company experienced a decline in revenue due to underperformance in instrument product reagent output, adjustments in product pricing affecting gross margins, increased marketing expenditures, and higher impairment losses compared to the previous year [1] Group 2: Strategic Adjustments - In response to the challenges, the company is actively adjusting its operational strategies with the support of its controlling shareholder, including management restructuring and marketing strategy adjustments to better align with market changes [2] - The company has significantly improved its cash flow through efforts in receivables collection, expense control, and asset disposals, ensuring sustainable development [2] Group 3: Stock Performance - Di Rui Medical's stock has faced a continuous decline, dropping 44% in 2024 and an additional 20% in 2025, currently valued at only 40% of its historical high in 2023 [2] Group 4: Management Changes - The company underwent a significant board overhaul in August of the previous year, with new appointments indicating a complete takeover by the China Resources Group, as the new chairman, general manager, and deputy general manager all come from the China Resources Pharmaceutical Group [2][3]